Abstract:
BACKGROUND:Fit patients with mantle cell lymphoma aged 18-65 years are usually given cytarabine and rituximab-based induction regimens followed by autologous haematopoetic stem-cell transplantation (HSCT). We investigated whether post-autologous HSCT maintenance with lenalidomide improves progression-free survival in this population. METHODS:This open-label, randomised, multicentre, phase 3 trial was done at 49 haematology and oncology units in Italy and Portugal. Eligible patients had Ann Arbor stage III or IV treatment-naive mantle cell lymphoma (or stage II plus bulky disease [≥5 cm] or B symptoms), and had evidence of cyclin D1 overexpression or the translocation t(11;14)(q13;q32). Patients were aged 18-59 years with Eastern Cooperative Oncology Group (ECOG) performance status 0-3, or aged 60-65 years with ECOG 0-2. After an optional prephase with vincristine and steroids (intravenous vincristine 1·4 mg/m2 on day 1, oral prednisone 100 mg [total dose] on days 1-5), patients were given three courses of R-CHOP (21-day cycle, intravenous rituximab 375 mg/m2 on day 1; intravenous doxorubicin 50 mg/m2, vincristine 1·4 mg/m2, and cyclophosphamide 750 mg/m2 on day 2; oral prednisone 100 mg/m2 on day 2-6). Patients then received one cycle of high-dose CTX (intravenous cyclophosphamide 4 g/m2 on day 1, intravenous rituximab 375 mg/m2 on day 4). After restaging, patients received two cycles of R-HD-cytarabine (high-dose intravenous cytarabine 2 g/m2 every 12 h on days 1-3, intravenous rituximab 375 mg/m2 on days 4 and 10). Patients with complete remission or partial remission proceeded to autologous HSCT and responding patients (complete remission or partial remission) with haematological recovery were randomly assigned (1:1) to receive 24 courses of oral lenalidomide maintenance (15 mg per day for patients with platelets >100 × 109 cells per L or 10 mg per day for platelets 60-100 × 109 cells per L, days 1-21 every 28 days) for 24 months, or observation. The primary endpoint was progression-free survival, measured in the randomised population. This study is registered with EudraCT (2009-012807-25) and ClinicalTrials.gov (NCT02354313). FINDINGS:Between May 4, 2010, and Aug 24, 2015, 303 patients were screened for inclusion and 300 patients were enrolled (median age 57 years, IQR 51-62; 235 [78%] male). 95 patients were excluded before randomisation, mostly due to disease progression, adverse events, and inadequate recovery. 104 patients were randomly assigned to the lenalidomide maintenance group and 101 patients to the observation group. 11 (11%) of 104 patients assigned to lenalidomide did not start treatment (3 withdrew, 6 adverse events or protocol breach, 2 lost to follow-up). At a median follow-up of 38 months after randomisation (IQR 24-50), 3-year progression-free survival was 80% (95% CI 70-87) in the lenalidomide group versus 64% (53-73) in the observation group (log-rank test p=0·012; hazard ratio 0·51, 95% CI 0·30-0·87). 41 (39%) of 104 patients discontinued lenalidomide for reasons including death or progression. Treatment-related deaths were recorded in two (2%) of 93 patients in the lenalidomide group (1 pneumonia, 1 thrombotic thrombocytopenic purpura), and one (1%) of 101 in the observation group (pneumonia). 59 (63%) of 93 patients in the lenalidomide group had grade 3-4 haematological adverse events versus 12 (12%) of 101 patients in the observation group (p<0·0001). 29 (31%) of 93 patients in the lenalidomide group and eight (8%) of 101 patients in the observation group had grade 3-4 non-haematological adverse events (p<0·0001), of which infections were the most common.Serious adverse events were reported in 22 (24%) of 93 patients in the lenalidomide group and five (5%) of 101 patients in the observation group. Pneumonia and other infections were the most common serious adverse events. INTERPRETATION:Despite non-negligibile toxicity, lenalidomide after autologous HSCT improved progression-free survival in patients with mantle cell lymphoma, highlighting the role of maintenance in mantle cell lymphoma. FUNDING:Fondazione Italiana Linfomi and Celgene.
journal_name
Lancet Haematoljournal_title
The Lancet. Haematologyauthors
Ladetto M,Cortelazzo S,Ferrero S,Evangelista A,Mian M,Tavarozzi R,Zanni M,Cavallo F,Di Rocco A,Stefoni V,Pagani C,Re A,Chiappella A,Balzarotti M,Zilioli VR,Gomes da Silva M,Arcaini L,Molinari AL,Ballerini F,Ferreridoi
10.1016/S2352-3026(20)30358-6subject
Has Abstractpub_date
2021-01-01 00:00:00pages
e34-e44issue
1issn
2352-3026pii
S2352-3026(20)30358-6journal_volume
8pub_type
杂志文章,多中心研究,随机对照试验abstract:BACKGROUND:High-dose methotrexate-based chemotherapy is standard for primary CNS lymphoma, but most patients relapse. High-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT) is supposed to overcome the blood-brain barrier and eliminate residual disease in the CNS. We aimed to investigate the safety ...
journal_title:The Lancet. Haematology
pub_type: 杂志文章,多中心研究
doi:10.1016/S2352-3026(16)30050-3
更新日期:2016-08-01 00:00:00
abstract:BACKGROUND:Multiple myeloma is one of the most common haematological malignancies in the USA and is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS). We aimed to assess the association between metformin use and progression of MGUS to multiple myeloma. METHODS:We did a retrospective co...
journal_title:The Lancet. Haematology
pub_type: 杂志文章
doi:10.1016/S2352-3026(14)00037-4
更新日期:2015-01-01 00:00:00
abstract:BACKGROUND:Treatment of venous thromboembolism in children is based on data obtained in adults with little direct documentation of its efficacy and safety in children. The aim of our study was to compare the efficacy and safety of rivaroxaban versus standard anticoagulants in children with venous thromboembolism. METH...
journal_title:The Lancet. Haematology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/S2352-3026(19)30219-4
更新日期:2020-01-01 00:00:00
abstract:BACKGROUND:Bortezomib with lenalidomide and dexamethasone (VRd) is a standard regimen for the front-line treatment of multiple myeloma. Panobinostat is approved in combination with bortezomib and dexamethasone in patients with myeloma who 'have been given at least two previous regimens including bortezomib and an immun...
journal_title:The Lancet. Haematology
pub_type: 杂志文章
doi:10.1016/S2352-3026(18)30174-1
更新日期:2018-12-01 00:00:00
abstract:BACKGROUND:The introduction of donors other than HLA-matched siblings has been a pivotal change in stem cell transplantation. We aimed to assess the evolution of outcomes within donor groups over time and explore whether donor-recipient HLA disparity might be advantageous in patients with aggressive disease. METHODS:I...
journal_title:The Lancet. Haematology
pub_type: 杂志文章
doi:10.1016/S2352-3026(19)30158-9
更新日期:2019-11-01 00:00:00
abstract:BACKGROUND:Leukoencephalopathy is observed in some children undergoing chemotherapy for acute lymphoblastic leukaemia, although its effects on long-term outcomes is unknown. This study examines the associations between acute leukoencephalopathy and neurobehavioural, neurocognitive, and brain white matter imaging outcom...
journal_title:The Lancet. Haematology
pub_type: 杂志文章
doi:10.1016/S2352-3026(16)30110-7
更新日期:2016-10-01 00:00:00
abstract::Evaluation of tolerability is increasingly relevant for patients with haematological malignancies treated with chronically administered therapies. Adverse events from these agents might affect the ability of patients to tolerate treatment over time. Conventional toxicity tables that include the incidence of high-grade...
journal_title:The Lancet. Haematology
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3026(20)30067-3
更新日期:2020-06-01 00:00:00
abstract:BACKGROUND:In patients with chronic lymphocytic leukaemia, achievement of a complete response with minimal residual disease of less than 0·01% (ie, <1 chronic lymphocytic leukaemia cell per 10 000 leukocytes) in bone marrow has been associated with improved progression-free survival. We aimed to explore the activity of...
journal_title:The Lancet. Haematology
pub_type: 杂志文章,多中心研究
doi:10.1016/S2352-3026(19)30113-9
更新日期:2019-09-01 00:00:00
abstract:BACKGROUND:Substantial evidence links exposure to moderate or high doses of ionising radiation, particularly in childhood, with increased risk of leukaemia. The association of leukaemia with exposure to low-dose (<100 mSv) radiation is less certain, although this is the dose range most relevant to the general populatio...
journal_title:The Lancet. Haematology
pub_type: 杂志文章
doi:10.1016/S2352-3026(18)30092-9
更新日期:2018-08-01 00:00:00
abstract:BACKGROUND:Effective treatment of trauma-induced coagulopathy is important; however, the optimal therapy is still not known. We aimed to compare the efficacy of first-line therapy using fresh frozen plasma (FFP) or coagulation factor concentrates (CFC) for the reversal of trauma-induced coagulopathy, the arising transf...
journal_title:The Lancet. Haematology
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3026(17)30077-7
更新日期:2017-06-01 00:00:00
abstract:BACKGROUND:Pegylated interferon alfa-2a is an immunomodulatory agent used to treat polycythemia vera. The durability of responses and long-term safety of this drug in patients with polycythaemia vera and essential thrombocythaemia have not been reported. Here, we present long-term efficacy and safety data from a single...
journal_title:The Lancet. Haematology
pub_type: 临床试验,杂志文章
doi:10.1016/S2352-3026(17)30030-3
更新日期:2017-04-01 00:00:00
abstract:BACKGROUND:The optimum preparative regimen for unrelated donor marrow transplantation in patients with severe aplastic anaemia remains to be established. We investigated whether the combination of fludarabine, anti-thymocyte globulin, and total body irradiation (TBI) would enable reduction of the cyclophosphamide dose ...
journal_title:The Lancet. Haematology
pub_type: 杂志文章
doi:10.1016/S2352-3026(15)00147-7
更新日期:2015-09-01 00:00:00
abstract:BACKGROUND:Anaemia and iron deficiency are common after post-bariatric abdominoplasty, which can involve removal of large areas of skin with associated blood loss. Because the oral absorbability of iron is reduced after bariatric surgery (through reduced intake, reduction of gastric acid secretion for conjugation of ir...
journal_title:The Lancet. Haematology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1016/S2352-3026(18)30071-1
更新日期:2018-07-01 00:00:00
abstract:BACKGROUND:In patients with pulmonary embolism, right ventricular dysfunction is associated with early mortality. The Hokusai-VTE study used N-terminal pro-brain natriuretic peptide (NT-proBNP) and right to left ventricular diameter ratio on CT as indicators of right ventricular dysfunction and reported that recurrent ...
journal_title:The Lancet. Haematology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/S2352-3026(16)30080-1
更新日期:2016-09-01 00:00:00
abstract:BACKGROUND:High-dose melphalan is of little benefit as a regimen for patients with relapsed or refractory myeloma undergoing an autologous stem-cell transplant (ASCT). The poor performance of single-agent melphalan in this setting prompted us to study a new high-dose combination of infused gemcitabine, busulfan, and me...
journal_title:The Lancet. Haematology
pub_type: 杂志文章
doi:10.1016/S2352-3026(17)30080-7
更新日期:2017-06-01 00:00:00
abstract::Machine learning is a branch of computer science and statistics that generates predictive or descriptive models by learning from training data rather than by being rigidly programmed. It has attracted substantial attention for its many applications in medicine, both as a catalyst for research and as a means of improvi...
journal_title:The Lancet. Haematology
pub_type: 杂志文章,评审
doi:10.1016/S2352-3026(20)30121-6
更新日期:2020-07-01 00:00:00
abstract:BACKGROUND:Intravenous rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1·5-6 h. A subcutaneous formulation could reduce patients' treatment burden and improve resource utilisation in health care. We aimed to show the pharmacokinetic non-inferiority of subcutaneous rituximab to...
journal_title:The Lancet. Haematology
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3026(17)30078-9
更新日期:2017-06-01 00:00:00
abstract:BACKGROUND:Ponatinib has shown efficacy in patients with refractory chronic myeloid leukaemia (CML) and in those with CML with a Thr315Ile mutation. We aimed to investigate the activity and safety of ponatinib as first-line treatment for patients with chronic-phase CML. METHODS:We did a single-arm, phase 2 trial at MD...
journal_title:The Lancet. Haematology
pub_type: 杂志文章
doi:10.1016/S2352-3026(15)00127-1
更新日期:2015-09-01 00:00:00
abstract:BACKGROUND:Although cytomegalovirus viral load is commonly used to guide pre-emptive therapy in the post-transplantation setting, few data are available correlating viraemia with clinical endpoints. We therefore investigated the association between cytomegalovirus viral load and mortality in the first year after haemop...
journal_title:The Lancet. Haematology
pub_type: 杂志文章
doi:10.1016/S2352-3026(15)00289-6
更新日期:2016-03-01 00:00:00
abstract:BACKGROUND:Hodgkin's lymphoma is one of the most common lymphoid neoplasms in young adults, but the low abundance of neoplastic Hodgkin/Reed-Sternberg cells in the tumour hampers the elucidation of its pathogenesis, biology, and diversity. After an incidental observation that genomic aberrations known to occur in Hodgk...
journal_title:The Lancet. Haematology
pub_type: 杂志文章
doi:10.1016/S2352-3026(14)00039-8
更新日期:2015-02-01 00:00:00
abstract:BACKGROUND:Venous thromboembolism is a common complication of cancer, but the risk of developing venous thromboembolism varies greatly among individuals and depends on numerous factors, including type of cancer. We aimed to develop and externally validate a clinical prediction model for cancer-associated venous thrombo...
journal_title:The Lancet. Haematology
pub_type: 杂志文章,多中心研究
doi:10.1016/S2352-3026(18)30063-2
更新日期:2018-07-01 00:00:00
abstract:BACKGROUND:Studies in patients with rheumatoid arthritis have shown that the rituximab biosimilar CT-P10 (Celltrion, Incheon, South Korea) has equivalent efficacy and pharmacokinetics to rituximab. In this phase 3 study, we aimed to assess the non-inferior efficacy and pharmacokinetic equivalence of CT-P10 compared wit...
journal_title:The Lancet. Haematology
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3026(17)30120-5
更新日期:2017-08-01 00:00:00
abstract:BACKGROUND:Mechanisms of red blood cell delivery and their contribution to the incidence of venous thromboembolism are not well understood in the clinical setting. We assessed whether red blood cell transfusion through peripherally inserted central catheters (PICCs) affects the risk of venous thromboembolism compared w...
journal_title:The Lancet. Haematology
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1016/S2352-3026(16)30132-6
更新日期:2016-12-01 00:00:00
abstract:BACKGROUND:Deep vein thrombosis (DVT) and pulmonary embolism are collectively known as venous thromboembolism (VTE), which is a common vascular disease and a major cause of morbidity and mortality worldwide. We compare effectiveness and safety of rivaroxaban versus warfarin in a prospective cohort of routine care patie...
journal_title:The Lancet. Haematology
pub_type: 杂志文章
doi:10.1016/S2352-3026(17)30054-6
更新日期:2017-05-01 00:00:00
abstract:BACKGROUND:Prevention of graft-versus-host disease (GvHD) without malignant relapse is the overall goal of allogeneic haemopoietic cell transplantation (HCT). We aimed to evaluate regimens using either maraviroc, bortezomib, or post-transplantation cyclophosphamide for GvHD prophylaxis compared with controls receiving ...
journal_title:The Lancet. Haematology
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3026(18)30221-7
更新日期:2019-03-01 00:00:00
abstract:BACKGROUND:Panobinostat (a pan histone deacetylase inhibitor) is approved in combination with bortezomib and dexamethasone for patients with relapsed multiple myeloma who have received two or more previous lines of therapy. We aimed to improve the safety of this combination and investigate efficacy by incorporating low...
journal_title:The Lancet. Haematology
pub_type: 杂志文章,多中心研究
doi:10.1016/S2352-3026(16)30165-X
更新日期:2016-12-01 00:00:00
abstract:BACKGROUND:Among the syndromes characterised by thrombotic microangiopathy, thrombotic thrombocytopenic purpura is distinguished by a severe deficiency in the ADAMTS13 enzyme. Patients with this disorder need urgent treatment with plasma exchange. Because ADAMTS13 activity testing typically requires prolonged turnaroun...
journal_title:The Lancet. Haematology
pub_type: 杂志文章
doi:10.1016/S2352-3026(17)30026-1
更新日期:2017-04-01 00:00:00
abstract:BACKGROUND:The INO-VATE study demonstrated efficacy and safety of inotuzumab ozogamicin versus standard care in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Here, we report the frequency of, and potential risk factors for, hepatotoxicity in patients in this trial and after treatment and subs...
journal_title:The Lancet. Haematology
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3026(17)30103-5
更新日期:2017-08-01 00:00:00
abstract:BACKGROUND:Gilbert's syndrome is a common inherited disorder of bilirubin metabolism, characterised by mild, unconjugated hyperbilirubinaemia. However, the effect of Gilbert's syndrome on the disposition of some drugs can lead to unexpected toxicity. We tested the hypothesis that patients undergoing myeloablative condi...
journal_title:The Lancet. Haematology
pub_type: 杂志文章
doi:10.1016/S2352-3026(16)30149-1
更新日期:2016-11-01 00:00:00
abstract:BACKGROUND:Sintilimab (Innovent Biologics, Suzhou, China), a highly selective, fully humanised, monoclonal antibody, blocks the interaction between PD-1 and its ligands. We aimed to assess the activity and safety profile of sintilimab in Chinese patients with relapsed or refractory classical Hodgkin lymphoma. METHODS:...
journal_title:The Lancet. Haematology
pub_type: 杂志文章,多中心研究
doi:10.1016/S2352-3026(18)30192-3
更新日期:2019-01-01 00:00:00